Drug intelligence / Profile preview

ENTCF-001

Development stage: Unknown
Lead developer: Entos Pharmaceuticals
Modality: Gene Therapies

Overview

ENTCF-001 is an investigational gene therapy developed by Entos Pharmaceuticals. It is currently in the discovery phase and has not yet entered clinical trials. The primary therapeutic area for ENTCF-001 is cystic fibrosis, a congenital disorder affecting the respiratory and digestive systems. The drug's mechanism of action, specific genetic target(s), and delivery modality have not been publicly disclosed as of June 2025. Its development status remains at the preclinical (discovery) stage, with no reported approvals or advanced clinical trial phases[1].

Beyond the preview

Go deeper on ENTCF-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENTCF-001.

Explore the full profile